OTCMKTS:TRLPF Acerus Pharmaceuticals (TRLPF) Stock Price, News & Analysis $0.22 0.00 (0.00%) (As of 07/21/2023) Add Compare Share Share Stock Analysis Stock Analysis Get Acerus Pharmaceuticals alerts: Email Address About Acerus Pharmaceuticals Stock (OTCMKTS:TRLPF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Acerus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.22▼$0.2250-Day Range$0.12▼$0.2252-Week Range$0.08▼$0.34VolumeN/AAverage Volume5,474 shsMarket Capitalization$56.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAcerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.Read More… Weird phenomenon on AMZN stock (Ad)What would you do if you knew that you could have bought Amazon on May 25th every year and walked away with a win?Click here to see the 10 best trades upcoming in 2024 for FREE Receive TRLPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TRLPF Stock News HeadlinesTakeda Pharmaceutical Co. Ltd. ADRFebruary 8, 2024 | wsj.com2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To BenefitJanuary 1, 2023 | seekingalpha.comInvest in the AI Boom: Top 5 Stocks to WatchBy now, you're well aware of the artificial intelligence boom. Big Tech has been investing billions of dollars into AI, and the market is projected to grow exponentially. According to several recent reports, the AI market, currently valued at around $100 billion, could grow twenty-fold by 2030 to more than $2 trillion. This explosive growth means it's time to consider these top AI stocks.September 18, 2024 | Daily Market Alerts (Ad)Acerus Reports Second Quarter 2022 Financial ResultsAugust 9, 2022 | financialpost.comAcerus Reports Fourth Quarter and Full Year 2021 Financial ResultsMarch 15, 2022 | financialpost.comSee More Headlines TRLPF Stock Analysis - Frequently Asked Questions How have TRLPF shares performed this year? Acerus Pharmaceuticals' stock was trading at $0.22 at the beginning of 2024. Since then, TRLPF stock has increased by 0.0% and is now trading at $0.22. View the best growth stocks for 2024 here. How were Acerus Pharmaceuticals' earnings last quarter? Acerus Pharmaceuticals Co. (OTCMKTS:TRLPF) announced its quarterly earnings data on Monday, November, 5th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01). The specialty pharmaceutical company had revenue of $1.58 million for the quarter. Acerus Pharmaceuticals had a negative net margin of 254.66% and a negative trailing twelve-month return on equity of 346.72%. How do I buy shares of Acerus Pharmaceuticals? Shares of TRLPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings11/05/2018Today9/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:TRLPF CUSIPN/A CIKN/A Webwww.aceruspharma.com Phone416-679-0771FaxN/AEmployees29Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,790,000.00 Net Margins-254.66% Pretax MarginN/A Return on Equity-346.72% Return on Assets-94.54% Debt Debt-to-Equity Ratio0.64 Current Ratio1.35 Quick Ratio0.90 Sales & Book Value Annual Sales$7.38 million Price / Sales7.71 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares258,615,000Free FloatN/AMarket Cap$56.90 million OptionableNot Optionable Beta2.60 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (OTCMKTS:TRLPF) was last updated on 9/18/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored625,000% GainThe recent crypto correction has shaken many investors, causing panic and uncertainty. But while others are fr...Crypto Swap Profits | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acerus Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acerus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.